Helsinki, Finland – Nasdaq announced today the results of the semi-annual review of the First North 25 Index (Nasdaq Stockholm: FN25).

Nanoform is included in Nasdaq First North 25 index and it becomes effective at market open on Monday, January 4th, 2021.

The First North 25 Index measures the performance of a selection of the largest and most traded securities listed on the Nasdaq First North Growth Markets in Denmark, Finland, Iceland and Sweden. The Index is reviewed semi-annually in January and July. For more information please see Nasdaq’s First North 25 Index Methodology on www.nasdaq.com.

For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. Nanoform’s capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com